DrugPatentWatch Database Preview
kynmobi Drug Profile
» See Plans and Pricing
Which patents cover Kynmobi, and what generic alternatives are available?
Kynmobi is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are fifteen patents protecting this drug.
This drug has two hundred and forty-two patent family members in twenty-four countries.
The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Kynmobi
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 16, 2031. This may change due to patent challenges or generic licensing.
There have been thirty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for kynmobi
| International Patents: | 242 |
| US Patents: | 15 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for kynmobi |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for kynmobi |
| What excipients (inactive ingredients) are in kynmobi? | kynmobi excipients list |
| DailyMed Link: | kynmobi at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for kynmobi
Generic Entry Date for kynmobi*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FILM;SUBLINGUAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for kynmobi
| Drug Class | Dopaminergic Agonist |
| Mechanism of Action | Dopamine Agonists |
US Patents and Regulatory Information for kynmobi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunovion Pharms Inc | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-005 | May 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Sunovion Pharms Inc | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Sunovion Pharms Inc | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Sunovion Pharms Inc | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Sunovion Pharms Inc | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for kynmobi
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 101346135 | Start Trial |
| Japan | 2009507854 | Start Trial |
| European Patent Office | 1968558 | Start Trial |
| Denmark | 1799453 | Start Trial |
| World Intellectual Property Organization (WIPO) | 03030881 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
